SAN DIEGO, March 13, 2025--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for ...
Explore Gossamer Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for GOSS. Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
- Gossamer to Present Preclinical Evidence of Synergistic Treatment Effect from Combination Seralutinib & Sotatercept in Models of PAH - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback